艾迪注射液联合低剂量沙利度胺和VAD方案治疗多发性骨髓瘤患者的临床疗效

Clinical efficacy of Aidi injection combined with low-dose thalidomide and VAD regimen in patients with multiple myeloma

目的探讨艾迪注射液联合低剂量沙利度胺和长春新碱+多柔比星+地塞米松(VAD)方案治疗多发性骨髓瘤(MM)患者的临床疗效。方法根据治疗方法的不同将124例MM患者分为对照组(n=61,低剂量沙利度胺联合VAD方案)和观察组(n=63,艾迪注射液联合低剂量沙利度胺和VAD方案)。比较两组患者的近期疗效、免疫功能、生活质量[卡氏功能状态(KPS)评分]及不良反应发生情况。结果观察组患者的疾病控制率为85.71%,高于对照组患者的70.49%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)及KPS评分均高于本组治疗前,CD8^(+)均低于本组治疗前,观察组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)及KPS评分均高于对照组,CD8^(+)低于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论艾迪注射液联合低剂量沙利度胺和VAD方案治疗MM效果显著,可改善患者的免疫功能,提高患者的生活质量,且具有一定的安全性。

Objective To investigate the clinical efficacy of Aidi injection combined with low-dose thalidomide and vincristine+doxorubicin+dexamethasone(VAD)regimen in patients with multiple myeloma(MM).Method A total of 124 MM patients were divided into control group(n=61,low-dose thalidomide+VAD regimen)and observation group(n=63,Aidi injection+low-dose thalidomide+VAD regimen)according to different treatment methods.The short-term efficacy,immune function,quality of life[Karnofsky performance status(KPS)]and adverse reactions were compared between the two groups.Result The disease control rate of the observation group was 85.71%,significantly higher than 70.49% of the control group(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)and KPS scores in the two groups were higher than those before treatment,and the levels of CD8^(+)were lower than those before treatment,with higher levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)and KPS scores and lower level of CD8^(+)in the observation group than those in the control group(P<0.05).There was no significant difference for the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Aidi injection combined with low-dose thalidomide and VAD regimen has a significant effect in the treatment of MM,which can improve the immune function and quality of life,and has moderate safety.